Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced plans to build a dedicated distributor network to support commercialization of its peptide portfolio across ...
Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative registry across a network of partner surgical facilities. The program ...
Vector Science & Therapeutics, Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced the expansion of its intellectual property portfolio to 15 patent applications developed and filed over ...
Vector Science and Therapeutics Corp. (TSXV: PAIN), a pharmaceutical-grade peptide and precision drug delivery company, today ...
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2026) - Vector Science and Therapeutics Corp. (TSXV: PAIN) (formerly OpenSesame Acquisition Corp.) ("Vector" or the "Company") is pleased to ...
Former Wisconsin Governor and U.S. Secretary of Health and Human Services Brings Extensive Healthcare Leadership to Pioneer of Transdermal Drug Delivery Technology MEQUON, Wis., April 30, 2026 ...
MEQUON, Wis., June 8, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board ...
Proprietary Magnetic Patch System Delivers Regenerative Peptides to Targeted Tissue Without Injection, with Built-In Confirmation of Successful Delivery MEQUON, Wis.
Year MLB Veteran and 2016 World Series Champion Joins Valor, Vector's Athlete Platform, to Make Sure the Next Generation Plays Longer and Hurts Less MEQUON, Wis., June 12, 2026 /PRNewswire/ -- Vector ...